AstraZeneca CEO Pascal Soriot

8. AstraZeneca ($AZN)
2014 revenue: $26.095 billion
2013 revenue: $25.711 billion

Since it mapped out its vision for its solo future in attempts to dodge a bid from Pfizer ($PFE), AstraZeneca has been looking up to some pretty lofty goals. And after its 2014 performance, hitting them might not be so easy.

In the fourth quarter, big guns Nexium and Crestor sank by 16% and 8%, respectively--gaps that'll only grow wider as generic competition sets in for the pair. That prospect led the British pharma to forecast a mid-single-digit drop in sales for 2015.

Still, it insists it's on track to return to growth by 2017 and hit $45 billion in 2023 sales--a 75% jump. One of the encouraging signs it pointed to was the strong performance of its growth platforms, which provide 53% of total revenue.

The leaders in that category: Brilinta, its slow-starting blood thinner, which jumped 70% on the year, and its diabetes franchise, which leaped 139%. Emerging markets and China also posted double-digit gains, as did respiratory--an area CEO Pascal Soriot has been working to beef up with some recent Actavis ($ACT) and Almirall deals.

All in all, the areas AZ's tapped for growth came through, collectively growing by 15%. Only Japan saw revenues sink, posting a decrease of 3%.

 -- Carly Helfand (email | Twitter)

For more:
AstraZeneca adds hefty share grant to CEO's £3.5M pay
AstraZeneca CEO says Pfizer won't come back. Oh, and that $45B goal? It's a stretch
AstraZeneca continues its respiratory land grab with $600M-plus Actavis deal
AstraZeneca toasts to independent living with big plans for its Pfizer-free future
With Pfizer's bid dead, AstraZeneca chief promises eyes on goal


Suggested Articles

Today, AmerisourceBergen kicked off its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward manufacturers.

With interim data for its COVID-19 vaccine still in the works, Pfizer is holding on to hope that it can still roll the shot out this year in the U.S.

While Eli Lilly has reasons to be excited about the future, one key medicine lagged expectations during the third quarter.